Search for dissertations about: "deubiquitinase"
Showing result 1 - 5 of 8 swedish dissertations containing the word deubiquitinase.
-
1. Identifying Essential Deubiquitinase Interactions and Targeting Protein Ubiquitination in Cancer
Abstract : Cancer is the second leading cause of death globally and is one of the most pressing health issues today. While significant advances have been made in cancer treatment, drug resistance and toxicity remain formidable obstacles to successful therapy. Thus, there is a need to find novel targets that pave the way for new cancer therapeutics. READ MORE
-
2. The role and mechanism of ubiquitin system in innate immune regulation
Abstract : Pattern-recognition receptors (PRRs) include the cell surface or endosomal membrane localized Toll-like receptors (TLRs) and the cytoplasmic PRRs such as RIG-I-like receptors (RLRs), NOD-like receptors (NLRs) and cytoplasmic DNA receptors (CDRs). Triggering of PRRs culminates in the transcriptional induction of pro-inflammatory cytokines and type I interferons (IFNs) that coordinate protection against pathogens but require tight control to avert inflammatory diseases. READ MORE
-
3. Mechanisms of modulation of PDGFRβ signaling
Abstract : Platelet-derived growth factors (PDGF) constitute a family of five functional dimers that bind to two structurally related tyrosine kinase receptors i.e. PDGF receptor α and β (PDGFRα and PDGFRβ, respectively), controlling cell growth, proliferation, and migration in cells of mesenchymal origin. READ MORE
-
4. Studies of PDGF receptor signaling in vitro and in vivo
Abstract : Platelet-derived growth factor receptor (PDGFR) signaling is essential for proliferation, migration and survival of cells of mesenchymal origin; however, its deregulation has been associated with various diseases, including cancer. The aim of this thesis was to clarify the molecular mechanisms of PDGFR signaling regulation. READ MORE
-
5. Identification and characterization of a proteasome deubiquitinase inhibitor
Abstract : The 26S proteasome has emerged as an attractive therapeutic target in the treatment of cancers. Proteasome inhibitors have been shown to selectively kill cancer cells. The FDA approval of bortezomib for the treatment of multiple myeloma and mantle cell lymphoma has clinically validated the 26S proteasome as a therapeutic target in oncology. READ MORE